Antitrust
Certiorari Granted in Auto Body Labor Prevailing Rate Litigation
In a case that potentially raises substantial constitutional issues regarding rate-setting with respect to auto body repair labor rates, the Rhode Island Supreme Court granted petitions for a writ of certiorari filed by the Property Casualty Insurers’ Association of America (“PCI”) and the Department of Business Regulation (“DBR”) on October 9, 2008. …
Eighth Circuit Dismisses Purported Class Action Against Insurers Alleging Price Discrimination
…
Antitrust Lawsuit Filed By Louisiana Against Insurers and Insurance Industry Participants Stays In Federal Court
…
New York Radiology Practice Sues Health Care Benefits Administration Firm Contracted With Major Health Care Insurers Alleging Antitrust Violations
…
EU: European Commission (the Commission) to examine the use of insurance block exemption regulation
The Commission has begun a public consultation to investigate the functioning of the Insurance Block Exemption Regulation (BER) and the impact on the various insurance markets in the European Union (EU). …
Wells Notice Received by Bond Insurer in Municipal Guaranteed Investment Contracts Antitrust Investigation
…
Class Action Antitrust Suit Brought Against Title Insurers in NY Federal Court
By complaint dated February 1, 2008, four named individuals commenced a class action lawsuit against fourteen (14) title insurance companies in the United States District Court for the Eastern District of New York alleging violations of antitrust laws. …
Bond Insurer Discloses Receipt of Wells Notice from U.S. Securities and Exchange Commission Related to Antitrust Investigation
…
Health Insurers’ Motion to Treble Damages Against Pharmaceutical Companies in Antitrust Case is Granted
On June 1, 2005, after a jury trial lasting over three weeks, a jury found for Blue Cross Blue Shield of Massachusetts (“BCBS-MA”), Blue Cross Blue Shield of Minnesota (“BCBS-MN”), Federated Mutual Insurance Company (“Federated”), and Health Care Service Corporation (“HCSC”) (collectively “Plaintiffs”) against Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc., Cambrex Corporation, and Gyma Laboratories (“Defendants”) on state law claims – agreement in unreasonable restraint of trade; conspiracy in unreasonable restraint of trade; monopolization; and, attempted monopolization – in the Lorazepam active pharmaceutical ingredient (“API”) market, Lorazepam tablet market and in the Clorazepate API and tablet markets. The jury awarded BCBS-MA $8,430,887, BCBS-MN $1,756,096, Federated $410,878.00, and HCSC $1,448,437.00 in damages. …